The global gallium-68 market is witnessing steady growth, driven by increasing adoption of nuclear imaging technologies and the rising prevalence of cancer worldwide. The market is projected to grow from US$ 782.36 million in 2022 to US$ 1,070.34 million by 2030, registering a CAGR of 4.0% during the forecast period (2022–2030). This growth is primarily attributed to the expanding use of gallium-68 in positron emission tomography (PET) imaging, especially for detecting prostate cancer and neuroendocrine tumors.

Gallium-68 is a positron-emitting radioisotope widely used in diagnostic imaging due to its high accuracy in tumor detection and localization. The increasing demand for early and precise diagnosis, along with advancements in radiopharmaceuticals, is significantly contributing to market expansion. Additionally, the growing number of nuclear medicine procedures and the introduction of innovative radiotracers are further boosting the demand for gallium-68 across healthcare systems globally.

Gallium-68 Market Segmentation Analysis

The gallium-68 market segmentation analysis provides a detailed understanding of the market structure based on application, end user, and geography. By application, the market is segmented into oncology, neurology, cardiology, and others. Among these, the oncology segment holds the largest share and is expected to register the highest growth rate during the forecast period. This dominance is due to the increasing use of gallium-68 in detecting prostate cancer and neuroendocrine tumors, where PET imaging plays a crucial role in accurate diagnosis and treatment planning.

Based on end user, the market is categorized into hospitals, diagnostic and imaging centers, and others. Hospitals account for the largest share of the market, driven by the availability of advanced diagnostic infrastructure and the increasing number of nuclear medicine procedures performed in hospital settings. Diagnostic and imaging centers are also experiencing growth due to the rising demand for specialized imaging services and outpatient diagnostic solutions.

Geographically, the gallium-68 market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America dominates the market due to advanced healthcare infrastructure, high adoption of nuclear imaging technologies, and increasing cancer prevalence. Meanwhile, Asia Pacific is expected to witness significant growth during the forecast period due to improving healthcare systems and rising awareness about early disease diagnosis.

Download Sample PDF - https://www.theinsightpartners.com/sample/TIPRE00029992

Market Drivers and Industry Dynamics

The gallium-68 market is primarily driven by the increasing prevalence of cancer, particularly prostate cancer and neuroendocrine tumors. The need for accurate and early diagnosis has led to a surge in demand for PET imaging technologies, where gallium-68 plays a critical role. The growing number of cancer cases globally is significantly boosting the adoption of gallium-68-based diagnostic solutions.

Another key driver is the rapid advancement in nuclear medicine and radiopharmaceuticals. The development of new gallium-68-based tracers and imaging agents has enhanced diagnostic accuracy, enabling better disease detection and treatment planning. Additionally, the increasing number of nuclear medicine procedures worldwide is contributing to market growth.

However, the market faces certain challenges, such as the short half-life of gallium-68, which requires immediate usage after production. This limitation poses logistical challenges in storage and transportation, potentially restraining market growth. Despite this, ongoing research and technological advancements are expected to address these challenges and create new opportunities for market expansion.

Regional Insights and Growth Opportunities

North America holds the largest share of the gallium-68 market, supported by advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and a strong presence of key market players. The region’s focus on early cancer detection and precision medicine is further driving demand for gallium-68-based imaging solutions.

Europe also represents a significant market, driven by increasing healthcare investments and the widespread use of nuclear medicine techniques. The region’s emphasis on research and development in radiopharmaceuticals is contributing to market growth.

Asia Pacific is expected to witness the fastest growth during the forecast period. Factors such as rising cancer incidence, improving healthcare infrastructure, and increasing awareness about advanced diagnostic techniques are driving market expansion in countries such as China and India. Additionally, government initiatives to enhance healthcare access and diagnostic capabilities are supporting market growth in the region.

Emerging markets in South & Central America and the Middle East & Africa are also showing potential growth opportunities due to increasing investments in healthcare and growing demand for advanced diagnostic solutions.

Competitive Landscape and Key Players

The gallium-68 market is competitive, with several global and regional players focusing on innovation, product development, and strategic collaborations. Key companies operating in the market include:

• Novartis AG
• Telix Pharmaceuticals (US) Inc
• IRE-ELiT SA
• ITM Medical Isotopes GmbH
• Eckert & Ziegler Radiopharma GmbH
• ARTMS Inc
• IBA Radiopharma Solutions
• Cardinal Health
• Rosatom
• Evergreen Theragnostics Inc

These companies are actively investing in research and development to introduce advanced radiopharmaceuticals and improve diagnostic capabilities. Strategic partnerships and geographic expansion are key strategies adopted by market players to strengthen their market position.

Future Outlook of the Gallium-68 Market

The future of the gallium-68 market looks promising, with steady growth expected through 2030. The increasing focus on early and accurate disease diagnosis, coupled with advancements in nuclear imaging technologies, will continue to drive market expansion.

Emerging trends such as the development of novel radiotracers, integration of advanced imaging systems, and expansion of nuclear medicine infrastructure are expected to create new growth opportunities. Additionally, the growing adoption of personalized medicine and targeted diagnostics will further enhance the demand for gallium-68-based solutions.

Overall, the gallium-68 market is set to play a crucial role in the global healthcare landscape, particularly in oncology diagnostics. With continuous technological advancements and increasing healthcare investments, the market is expected to witness sustained growth, making it a vital segment within the radiopharmaceutical industry.

Top Trending Reports:

Biotechnology Market Share, Demand & Growth by 2034

Genomics Market Dynamics and Developments by 2031

Molecular Biology Enzymes, Kits, and Reagents Market Size and Competitive Analysis by 2028

About Us

The Insight Partners is a leading global market research and consulting firm dedicated to delivering actionable insights across diverse industries. The company specializes in providing comprehensive reports that help businesses understand market dynamics, identify growth opportunities, and develop effective strategies. With a strong emphasis on data-driven analysis, The Insight Partners supports organizations in making informed decisions and achieving long-term success.

Contact Us

The Insight Partners
Email: sales@theinsightpartners.com
Phone: +1-646-491-9876
Website: www.theinsightpartners.com

Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish